12:37 PM EDT, 05/13/2024 (MT Newswires) -- Novo Nordisk A/S ( NVO ) shares were up 3% in recent Monday trading after the drugmaker said its Mim8 antibody was found to benefit patients with hemophilia A, a condition where blood does not clot properly.

Results from the late-stage Frontier 2 trial showed that Mim8 was better at preventing bleeding episodes versus other treatments previously used for hemophilia A, the company said.

Both the once-weekly and once-monthly dosing schedules of Mim8 were found to be beneficial in people aged 12 years and up with haemophilia A, with or without inhibitors, Novo Nordisk ( NVO ) said.

The company plans to seek first regulatory approval of the antibody towards the end of 2024.

Price: 132.56, Change: +4.14, Percent Change: +3.22